Does the shoulder evidence show what may ease soreness?

Does an abnormal scan explain the soreness?

Not always. Rotator cuff wear becomes more common over time. Your rotator cuff includes the small muscles and tendons that hold and lift the arm. A sore shoulder may show the same scan change as a comfortable shoulder.

The person doing your exam checks where motion stops and where strength drops. Scans help more after a fall, sudden weakness or a lasting loss of motion. They may also guide a talk about surgery.

Your scan matters when its finding matches what the arm can do.

Can rotator cuff treatment without surgery help?

Many rotator cuff problems first improve when you reduce overhead work and do steady strength exercises. Easy movement keeps the shoulder from getting stiffer. Progress can take time, so a difficult week doesn't decide whether exercise is working.

Surgery may matter after a major injury or when strength stays poor. One long study looked at decompression surgery for soreness above the shoulder tendons. That operation removes bone spurs and soft tissue above those tendons. Over time, it worked no better than exercise.

If strength drops after an injury, get examined soon.

Does regenerative medicine for shoulder pain use blood or other body tissue?

Yes. The term regenerative medicine covers care prepared from blood or other body tissue. Platelet-rich plasma, called PRP, is the platelet-heavy portion made after blood is spun. For some shoulder-tendon soreness, research compared PRP with cortisone.

The early results were similar. At six months, the PRP group had slightly better arm-use scores and eight-tenths of a point less soreness. That small result doesn't show tendon repair. It also doesn't answer questions about frozen shoulder or severe joint wear, which are different problems.

QC Kinetix medical providers, the people who carry out your exam, offer Peoria visits to discuss these non-surgical treatments.

Sources

1. The August 2025 AAOS Evidence-Based Clinical Practice Guideline on Management of Rotator Cuff Injuries issued 25 recommendations and 4 consensus statements. Among its updates it clearly RESTRICTS the use of platelet-rich plasma and marrow stimulation in rotator cuff repair, limits prolotherapy in full-thickness tears, establishes CT as an adjunctive imaging modality, and endorses early mobilization after repair of small-to-medium tears.

   Ye Y, et al. — [Interpretation of the 2025 American Academy of Orthopaedic Surgeons (AAOS) on Management of Rotator Cuff Injuries Evidence-Based Clinical Practice Guideline].. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, 2026. DOI: 10.7507/1002-1892.202511084.

2. At 10 years, arthroscopic subacromial decompression offered NO benefit over placebo surgery for subacromial pain syndrome: the mean difference in VAS pain was -1.5 points (95% CI -8.6 to 5.6) at rest and -3.2 points (-13.0 to 6.5) on arm activity, against a minimally important difference of 15. It also showed no benefit over exercise therapy.

   Kanto K, et al. — Arthroscopic subacromial decompression versus placebo surgery for subacromial pain syndrome: 10 year follow-up of the FIMPACT randomised, placebo surgery controlled trial.. BMJ, 2025. DOI: 10.1136/bmj-2025-086201.

3. In a nationally representative Finnish population sample of 602 adults aged 41-76 who had bilateral 3-Tesla shoulder MRI regardless of symptoms, rotator cuff abnormalities were found in 98.7% of participants (25% tendinopathy, 62% partial-thickness tear, 11% full-thickness tear). Abnormalities were present in 96% of ASYMPTOMATIC shoulders. Only full-thickness tears were more common in symptomatic shoulders, and that difference all but disappeared after adjustment (absolute difference 0.8%, 95% CI -3.4% to 6.0%).

   Ibounig T, et al. — Incidental Rotator Cuff Abnormalities on Magnetic Resonance Imaging.. JAMA Intern Med, 2026. DOI: 10.1001/jamainternmed.2025.7903.

4. A 2026 meta-analysis of 10 randomized trials (n=591) found PRP and corticosteroid indistinguishable at 3-6 weeks and 3 months, with PRP pulling ahead at 6 months: ASES +10.8 (95% CI 4.71-16.80), Constant-Murley +10.7 (1.21-20.27) and VAS pain -0.8 (-1.45 to -0.18), plus fewer adverse events (RR 0.66, 0.44-0.99). The authors describe the benefit as statistically significant but CLINICALLY MODEST.

   Yuwarungsikul C, et al. — Platelet-rich plasma provides modest but durable functional benefit over corticosteroid for rotator cuff tendinopathy: A systematic review and meta-analysis of randomized controlled trials.. Knee Surg Sports Traumatol Arthrosc, 2026. DOI: 10.1002/ksa.70416.

5. FDA states plainly that no stem cell, exosome, stromal vascular fraction, umbilical cord blood, Wharton's jelly or amniotic-fluid product has been approved for the treatment of ANY orthopedic condition - it names osteoarthritis, tendonitis, disc disease, tennis elbow, back pain, hip pain, knee pain, neck pain and shoulder pain individually. The only FDA-approved stem cell products in the United States are cord-blood-derived blood-forming stem cells for disorders of the hematopoietic system, and there are currently no FDA-approved exosome products.

   US Food and Drug Administration, Center for Biologics Evaluation and Research — Consumer Alert on Regenerative Medicine Products Including Stem Cells and Exosomes. FDA, 2020.